作者: B Reckzeh , H Merte , K H Pflüger , R Pfab , M Wolf
DOI: 10.1200/JCO.1996.14.4.1071
关键词: Lung cancer 、 Immunodeficiency 、 Surgery 、 Gastroenterology 、 Chemotherapy 、 Radiation therapy 、 Internal medicine 、 Lymphocytopenia 、 Leukopenia 、 Medicine 、 Paclitaxel 、 Respiratory disease
摘要: PURPOSEIn a phase II trial with paclitaxel and simultaneous radiotherapy in non-small-cell lung cancer (NSCLC) patients, an unexpected high incidence of interstitial pneumonias was observed. The type immunodeficiency associated this treatment approach is characterized.PATIENTS AND METHODSFifteen patients inoperable stage IIIA/B NSCLC were treated as 3-hour infusion on day 1 weeks to 3 6 8 at dose levels between 50 mg/m2 86 daily doses 2 Gy, 5 days per week, up total 56 Gy. Hematologic parameters lymphocyte subsets monitored.RESULTSFourteen are assessable for response. overall response rate 78%, four major responses, six partial remissions, minor responses. toxic effect observed moderate severe protracted lymphocytopenia (380 +/- 310/microL) all patients. Seven developed pn...